GLP-1 receptor activation primarily occurs in the brain's hypothalamic regions, directly suppressing appetite and food-seeking behaviors
law, compounding may occur through patient-specific prescriptions (503A pharmacies) or by FDA-registered outsourcing facilities (503B), and is generally permitted only when there is a legitimate clinical need or drug shortage
Estrogen decline, insulin resistance, and midlife weight gain in menopause The transition to menopause is associated with a decline in estrogen, demonstrating an important link between hormonal changes, insulin resistance, and the common experience of midlife weight gain, particularly around the abdomen
However, starting July 1, 2026, a temporary program called the Medicare GLP-1 Bridge will provide limited coverage to some weight loss drugs